Clinical Trials on Care Acceptor, Health in United States

Total 81540 results

University of Pennsylvania

Active, not recruiting

Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT

Healthy Volunteer | D3 Dopamine Receptor | Cocaine-dependent

United States
National Institute of Mental Health (NIMH)

Completed

PET Imaging of Brain mGluR5 Receptors Using [18F]SP203

Healthy | PET Scan | Glutamate Receptor | mGlur5 Protein | Excitatory Amino Acid Receptors | Drug Kinetics

United States
National Institute of Nursing Research (NINR)

Not yet recruiting

A Natural History Study of RYR1-Related Disorders

Ryanodine Receptor 1-Related Myopathy | Ryanodine Receptor 1 Related Disorders

United States
Sanofi

Completed

Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).

Chronic Heart Failure

Canada, United States, United Kingdom
Yale University
Janssen Scientific Affairs, LLC

Not yet recruiting

PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor (emo_to2)

Muscarinic Receptor Occupancy

United States
Colorado State University

Completed

Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults

Receptor Blockade

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Genentech, Inc.; Translational Breast Cancer... and other collaborators

Terminated

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Stage IV Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma

United States
Daiichi Sankyo, Inc.

Completed

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

Hypertension | Mineralocorticoid Receptor Antagonist

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

Inflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast Cancer

United States
National Institute of Mental Health (NIMH)

Completed

Specific PET Radioligand Binding to Translocator Protein

Baseline | Blocking Receptor Binding

United States
AC Camargo Cancer Center
H. Lee Moffitt Cancer Center and Research Institute

Completed

Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression (HORMONET)

Neuroendocrine Tumors | Estrogen Receptor Positive Tumor | Progesterone Receptor Positive Tumor

United States, Brazil
University of Washington
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Recruiting

Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression

Prostate Cancer

United States
National Institute of Arthritis and Musculoskeletal...
National Institutes of Health Clinical Center (CC)

Completed

Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)

DIRA

United States
Washington University School of Medicine

Completed

Pilot - Peri-operative Beta Blockade

Adrenergic Beta-Receptor Blockader | Troponin Levels | Cardiomyopathy, Post-surgical

United States
National Cancer Institute (NCI)

Terminated

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive

United States
City of Hope Medical Center
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Metastatic Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Androgen Receptor Positive

United States
AstraZeneca

Completed

AZD5069 Neutrophil Function Study

Chemokine Receptor 2 (CXCR2) Antagonist

United Kingdom
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)

Terminated

Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users

Cognitive Function | Methamphetamine Abuse | Dopamine D2/3 Receptor Availability

United States
National Cancer Institute (NCI)

Completed

F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast Cancer

United States
AstraZeneca

Completed

Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors

Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor

United Kingdom, United States
Duke University
United States Department of Defense

Active, not recruiting

Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer

Healthy | Breast Cancer | Estrogen Receptor-positive Breast Cancer

United States
National Cancer Institute (NCI)

Terminated

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive and other conditions

United States
Adrienne G. Waks
Eli Lilly and Company; Verastem, Inc.

Recruiting

VS-6766+Abema+Fulv in Met HR+/HER- BC

Breast Cancer | Hormone Receptor-positive Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer

Invasive Breast Carcinoma | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive

United States
Yale University
VA Office of Research and Development

Completed

The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects (GuaKet)

NMDA Receptor Function

United States
University of California, Irvine
Applied Biology, Inc.

Withdrawn

COVID-19 In-vitro Diagnostic Test and Androgen Receptor Gene Expression

Covid19 | Androgen Receptor Gene Overexpression

United States
National Cancer Institute (NCI)

Completed

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Adult Solid Neoplasm

United States
Jose Pablo Leone
Eli Lilly and Company; Translational Breast Cancer Research Consortium (TBCRC)

Recruiting

ETHAN - ET for Male BC

Male Breast Cancer | Hormone Receptor-positive Breast Cancer | Hormone Receptor Negative Breast Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Carcinoma | Stage IV Breast Cancer | Invasive Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative...

United States
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma

United States
Oana Danciu, MD
Pfizer; Big Ten Cancer Research Consortium

Active, not recruiting

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

Metastatic Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Estrogen Receptor Positive Breast Cancer | Progesterone Receptor Positive Tumor

United States
Wake Forest University

Recruiting

Effect of Beet-root Juice and PBM Treatments on Muscle Fatigue

Healthy Aging | Health Care Utilization

United States
National Cancer Institute (NCI)

Completed

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

Hormone Receptor-Positive Breast | Gynecologic | Desmoid | Hormone Receptor-Positive Neoplasms

United States
University of Pennsylvania
Independence Blue Cross; Penn Medicine Center for Health Care Innovation

Active, not recruiting

Advanced Heart Care at Home (AHCAH)

Heart Failure | Palliative Care | Health Care Utilization | Quality Improvement

United States
Antonio Giordano, MD
Cardiff Oncology

Recruiting

Onvansertib + Paclitaxel In TNBC

Breast Cancer | Metastatic Breast Cancer | Inflammatory Breast Cancer | Invasive Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast Carcinoma | HER2-negative Breast Cancer | Triple Negative Breast Cancer (TNBC) | Hormone Receptor Negative Breast Carcinoma | Hormone Receptor/Growth Factor...

United States
Ellipses Pharma

Recruiting

Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer

Metastatic Breast Cancer | Hormone Receptor-positive Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer

United States, Spain, United Kingdom
Namida Lab

Enrolling by invitation

Validation of a Tear-based Screening Assay for Breast Cancer

Healthy | Breast Cancer | Health Knowledge, Attitudes, Practice | Health Care Utilization | Breast Cancer Female | Health Personnel Attitude | Health Care Acceptability

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma

United States
University of Wisconsin, Madison

Not yet recruiting

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

Neuroendocrine Tumors | Somatostatin Receptor-positive Neuroendocrine Tumor

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

Stage IV Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Triple-negative Breast Carcinoma | Progesterone Receptor-negative

United States
Northwestern University
National Cancer Institute (NCI); MedImmune LLC; Avon Breast Cancer Foundation

Completed

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative

United States
University of Arizona
National Cancer Institute (NCI)

Completed

Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer

Stage IV Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor Positive Tumor

United States
University of Wisconsin, Madison
Wisconsin Partnership Program

Completed

Today Not Tomorrow Pregnancy and Infant Support Program (TNT- PISP)

Infant Death | Infant Mortality | Mental Health | Healthcare Disparities | Social Determinants of Health | Physician-Patient Relations | Minority Health | Prenatal Care | Adverse Childhood Experiences | Prenatal Stress | Racial Bias | Trust | Quality of Care | Maternal Child Health | Health Problems in Pregnancy | Support... and other conditions

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Astellas Pharma US, Inc.

Active, not recruiting

Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

Salivary Cancer

United States
National Cancer Institute (NCI)

Completed

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Estrogen Receptor Positive | Progesterone Receptor Positive | Postmenopausal | KIT Positive | PDGFR Positive

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | Progesterone Receptor Positive

United States

Clinical Trials on Care Acceptor, Health in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations